Tripos Introduces LeadDiscovery Program
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
Tripos, Inc. has announced the introduction of its LeadDiscovery program, designed to develop leads for its pharmaceutical and biotechnology customers.
"This new program draws on the power of our combined informatics and laboratory capabilities to enable our customers to develop new active leads quickly and efficiently," said Dr. John P. McAlister, president and CEO of Tripos.
He said, "LeadDiscovery provides Tripos and its customers with commercialization opportunities at a time when the pharmaceutical industry is looking for early-stage drug candidates that have achieved proof of principle and are more likely to enter the clinical phase."
According to Tripos, it has created proprietary LeadDiscovery compound sets that contains selective inhibitors with demonstrated potency and selectivity toward G-protein-coupled receptors (GPCRs) and kinases and have the potential to generate intellectual property for customers.
Each LeadDiscovery set is based on multiple scaffolds that have shown activity and selectivity for the specified gene family in biological assays.
These compounds were designed and developed using Tripos' proprietary technologies including ChemSpace® to identify active structures from known leads combined with medicinal chemistry expertise employed at Tripos' state-of-the-art facility in Bude, England.
Tripos is focusing initially on these two target areas because approximately 30 percent of all currently marketed drugs act on one or more GPCRs, and kinases play an active role in cancer and inflammatory diseases.
However, future LeadDiscovery research is expected to expand into programs for ion channels and proteases.
Tripos offers that Pharmaceutical and biotech companies can access its LeadDiscovery compounds for screening against their own targets at their research laboratories, and may elect to acquire ownership rights from Tripos for selected compounds.
"Our new LeadDiscovery program provides customers with access to exciting leads through a low-risk, high-return business model," said Dr. Mark Allen, senior vice president and general manager of Tripos Discovery Research, Ltd.
He adds, "Our proven capabilities in rapid hit follow-up and lead optimization present an unparalleled opportunity for our clients to accelerate their discovery research activities."
"This new program draws on the power of our combined informatics and laboratory capabilities to enable our customers to develop new active leads quickly and efficiently," said Dr. John P. McAlister, president and CEO of Tripos.
He said, "LeadDiscovery provides Tripos and its customers with commercialization opportunities at a time when the pharmaceutical industry is looking for early-stage drug candidates that have achieved proof of principle and are more likely to enter the clinical phase."
According to Tripos, it has created proprietary LeadDiscovery compound sets that contains selective inhibitors with demonstrated potency and selectivity toward G-protein-coupled receptors (GPCRs) and kinases and have the potential to generate intellectual property for customers.
Each LeadDiscovery set is based on multiple scaffolds that have shown activity and selectivity for the specified gene family in biological assays.
These compounds were designed and developed using Tripos' proprietary technologies including ChemSpace® to identify active structures from known leads combined with medicinal chemistry expertise employed at Tripos' state-of-the-art facility in Bude, England.
Tripos is focusing initially on these two target areas because approximately 30 percent of all currently marketed drugs act on one or more GPCRs, and kinases play an active role in cancer and inflammatory diseases.
However, future LeadDiscovery research is expected to expand into programs for ion channels and proteases.
Tripos offers that Pharmaceutical and biotech companies can access its LeadDiscovery compounds for screening against their own targets at their research laboratories, and may elect to acquire ownership rights from Tripos for selected compounds.
"Our new LeadDiscovery program provides customers with access to exciting leads through a low-risk, high-return business model," said Dr. Mark Allen, senior vice president and general manager of Tripos Discovery Research, Ltd.
He adds, "Our proven capabilities in rapid hit follow-up and lead optimization present an unparalleled opportunity for our clients to accelerate their discovery research activities."
